PBA 033
Alternative Names: PBA-033Latest Information Update: 19 Mar 2021
At a glance
- Originator Path BioAnalytics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Coeliac disease; Respiratory tract disorders
Most Recent Events
- 02 Mar 2021 PBA 033 is available for licensing as of 02 Mar 2021. http://pathbioanalytics.com/#shapely_home_parallax-22
- 02 Mar 2021 Preclinical trials in Coeliac disease in USA (unspecified route) (Path BioAnalytics pipeline, March 2021)
- 02 Mar 2021 Preclinical trials in Respiratory tract disorders in USA (unspecified route) (Path BioAnalytics pipeline, March 2021)